Sarepta Therapeutics, Inc.SRPTNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank97
5Y CAGR+76.5%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
+76.5%/yr
Long-term compound
Percentile
P97
Near historical high
vs 5Y Ago
17.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 392.72% |
| Q3 2025 | -118.67% |
| Q2 2025 | 136.44% |
| Q1 2025 | -1266.20% |
| Q4 2024 | 149.98% |
| Q3 2024 | -658.96% |
| Q2 2024 | 95.00% |
| Q1 2024 | -286.07% |
| Q4 2023 | 52.60% |
| Q3 2023 | -10.91% |
| Q2 2023 | 35.98% |
| Q1 2023 | -118.20% |
| Q4 2022 | -34.85% |
| Q3 2022 | 1.94% |
| Q2 2022 | 28.89% |
| Q1 2022 | -238.47% |
| Q4 2021 | 76.39% |
| Q3 2021 | -16.11% |
| Q2 2021 | 42.91% |
| Q1 2021 | 0.80% |
| Q4 2020 | 22.90% |
| Q3 2020 | -107.84% |
| Q2 2020 | -120.49% |
| Q1 2020 | 439.77% |
| Q4 2019 | -135.09% |
| Q3 2019 | 19.56% |
| Q2 2019 | 41.06% |
| Q1 2019 | -14.09% |
| Q4 2018 | -6.46% |
| Q3 2018 | -6.03% |
| Q2 2018 | -161.48% |
| Q1 2018 | -36.33% |
| Q4 2017 | 45.81% |
| Q3 2017 | 25.70% |
| Q2 2017 | -38.96% |
| Q1 2017 | 24.81% |
| Q4 2016 | -36.90% |
| Q3 2016 | -40.21% |
| Q2 2016 | 29.24% |
| Q1 2016 | -89.79% |